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The initial steps in the pathogenesis of acute
leukemia remain incompletely understood. The TEL-
AML1 gene fusion, the hallmark translocation in
Childhood Acute Lymphoblastic Leukemia and the
first hit, occurs years before the clinical disease,
most often in utero.We have generatedmice inwhich
TEL-AML1 expression is driven from the endogenous
promoter and can be targeted to specific popula-
tions. TEL-AML1 renders mice prone to malignancy
after chemical mutagenesis when expressed in
hematopoietic stem cells (HSCs), but not in early
lymphoid progenitors. We reveal that TEL-AML1
markedly increases the number of HSCs and
predominantly maintains them in the quiescent (G0)
stage of the cell cycle. TEL-AML1+ HSCs retain self-
renewal properties and contribute to hematopoiesis,
but fail to out-compete normal HSCs. Our work
shows that stem cells are susceptible to subversion
by weak oncogenes that can subtly alter their molec-
ular program toprovide a latent reservoir for theaccu-
mulation of further mutations.
INTRODUCTION
Acute leukemias, malignancies associated with progressive
accumulation of arrested immature blood cell precursors (blasts)
in the bone marrow, progress rapidly and often appear without
an obvious prodrome (Pui et al., 2008). However, tracking of
chromosomal translocations characteristic of different forms of
acute leukemia in patients has established that the inciting
molecular abnormalities may predate the onset of overt disease
by years (Mori et al., 2002; Pui et al., 2008). Such a long latency
suggests a multistep molecular pathogenesis. Nonetheless, the
cascade of genetic events that ultimately results in acute
leukemia, as well as the contribution of individual ‘‘hits,’’ partic-ularly those that initiate the process, remains incompletely
understood.
Hematopoietic stem cells (HSCs) are the only blood-forming
cells in the bone marrow capable of long-term self-renewal
(Orkin and Zon, 2008) and, therefore, might have the unique
potential to serve as a reservoir for mutations that, by them-
selves, are insufficient to immortalize their target cells. Retroviral
expression of potent leukemic fusion oncogenes, such as MLL-
AF9, MLL-ENL, or MOZ-TIF2, have been shown to endow short-
lived progenitors with the capacity for sustained self-renewal
(division without differentiation) (Krivtsov et al., 2006), but
expression of MLL-AF9 from its endogenous promoter in
a knockin model preferentially results in transformation of
HSCs (Chen et al., 2008). In the absence of oncogene-induced
self-renewal, the more differentiated progeny of HSCs, with the
mutations that may have occurred in them, disappear from the
bone marrow within several weeks. While HSCs have been firmly
implicated in sustaining chronic forms of leukemia, such as
chronic myelogeneous leukemia (CML) and myelodysplastic
syndrome (MDS), the involvement of HSCs at the time of overt
acute leukemia is dependent on the specific subtype, with
consistent involvement in acute myeloid leukemia (AML) (Bonnet
and Dick, 1997) and some, but not all, forms of acute lymphoid
leukemia (ALL) (Castor et al., 2005; Cox et al., 2004; Hotfilder
et al., 2002). It is presumed, but unproven, that HSCs provide
a reservoir in the latent phase of acute leukemia, during which
preleukemic molecular lesions may accumulate prior to progen-
itor immortalization. Since chromosomal translocations that
target core-binding factor (CBF), the most common molecular
abnormalities in both AML and ALL, have weak, if any, trans-
forming capacity as single hits (Speck and Gilliland, 2002), it is
tempting to speculate that their presence might be required at
the HSC stage in order to foster survival of HSCs in the bone
marrow until additional molecular hits are acquired in the evolu-
tion to frank malignancy. However, direct evidence on behalf of
this model is lacking.
Core-binding factor is a heterodimeric transcriptional regu-
lator comprised of AML1 (RUNX1, CBFA2, and PEBP2aB), the
DNA-binding component, and CBFb, which increases AML1’sCell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc. 43
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AML1 or CBFb in mice leads to embryonic lethality at embryonic
day (E) 12.5 to 13.5 with hematopoietic failure (Speck and Gilli-
land, 2002). Specifically, AML1 is essential for the emergence
of HSCs from vascular endothelium in the embryo (Chen et al.,
2009). The most prevalent chromosomal translocations involving
either AML1 or CBFb are (1) t(8;21), which gives rise to the AML1-
ETO fusion oncogene in 15% of AML; (2) inversion (16), which
gives rise to the CBFb-SMMHC in10% of AML; and (3) t(12;21),
which gives rise to the TEL-AML1 fusion oncogene in 25% of
pediatric ALL (Speck and Gilliland, 2002). The mechanisms
involved in the tight association between these translocations
and their particular leukemic cell phenotypes are largely unre-
solved. Remarkably, recreation of AML1-ETO or CBFb-SMMHC
in mice produces heterozyogous embryonic lethality with pheno-
types strongly resembling those resulting from knockout of
AML1 or CBFb (Speck and Gilliland, 2002). These findings
have been interpreted to suggest that translocations involving
CBF act as dominant-negative inhibitors of CBF to induce
leukemia. Accordingly, AML1 haploinsufficiency predisposes
to leukemia (Kundu et al., 2005; Song et al., 1999). However, in
the adult mouse, neither AML1 loss (Growney et al., 2005; Ichi-
kawa et al., 2004) nor induced expression of AML1-ETO or
CBFb-SMMH is sufficient to induce leukemia as a single hit
(Speck and Gilliland, 2002).
TEL-AML1 is the initiating molecular lesion in the largest
genetically defined group in childhood leukemia. It is unique
among the leukemia fusion proteins involving CBF in that it is
associated exclusively with pediatric ALL, rather than AML
(Speck and Gilliland, 2002). The leukemic cells appear arrested
at the pro-B-cell stage; they initiate, but fail to complete, immu-
noglobulin gene rearrangements (Panzer-Grumayer et al., 2005).
Twin studies and retrospective analysis of blood taken at birth
demonstrates that the leukemia is initiated in utero (Ford et al.,
1998; Mori et al., 2002), yet leukemia typically is not overt until
the third or fourth year of life. TEL-AML1 is detectable in cord
blood samples at a frequency 100-fold in excess of the risk
of leukemia, consistent with the notion that additional molecular
hits are required for malignant transformation (Greaves, 2003;
Mori et al., 2002). Correspondingly, it was recently revealed by
high-resolution genome-wide analysis that multiple additional
genetic lesions are present in overt TEL-AML1-associated
leukemia (Mullighan et al., 2007). Events during the covert pre-
leukemic phase of the disease appear to be diverse. In many
instances, analyses of immunoglobulin receptor rearrangements
have demonstrated that preleukemic clones can be propagated
after B-lineage commitment (Ford et al., 1998; Hong et al., 2008).
Consistent with this conclusion, retroviral transduction of TEL-
AML1 in murine and human models suggested that TEL-AML1
may promote self-renewal of early B cells (Hong et al., 2008;
Morrow et al., 2004). Alternatively, it has been documented
that different clones may share the same TEL-AML1 fusion but
have independent B cell receptor rearrangements, demon-
strating that the initial hit may be propagated in cells not yet
committed to the B cell lineage (Pine et al., 2003; Weston
et al., 2001). Consistent with the latter, expansion of early
progenitors has also been detected after retroviral expression
of TEL-AML1 (Morrow et al., 2004; Tsuzuki et al., 2004). Surpris-
ingly, TEL-AML1 is detectable in adult blood samples at least as44 Cell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc.frequently as in cord bloods (Eguchi-Ishimae et al., 2001; Olsen
et al., 2006), and yet adult ALL is rarely, if ever, associated with
TEL-AML1 expression. The reason for the age restriction of
TEL-AML1-associated leukemia remains unknown.
In order to explore how TEL-AML1 perturbs normal hemato-
poiesis to initiate a cascade of events that ultimately leads to
childhood leukemia, we have recreated a TEL-AML1 allele by
conditional gene-targeting in mice. This approach has allowed
us to define the impact of physiologic expression levels of
TEL-AML1, regulated by the endogenous TEL locus, on HSCs
and early lineage differentiation. Our study reveals that key
features of TEL-AML1-associated leukemia may be explained
by its impact on hematopoietic development and establishes
that HSCs can be corrupted to provide a reservoir for weak
oncogenes in the latent phase of acute leukemia.
RESULTS
TEL-AML1 Expression Is Permissive for Embryonic
Development and Normal B Cell Maturation
in the Postnatal Period
We generated a mouse allele in which a truncated human AML1
c-DNA is targeted to the first base pair of exon VI of TEL/ETV6
(TEL), such that normal splicing generates an mRNA encoding
a hybrid protein with a breakpoint identical to that found in trans-
location t(12;21) (Figures 1A–1C and Figure S1 available online).
TEL-AML1 expression is under the control of the endogenous
TEL promoter, as in leukemic cells. A loxP flanked ‘‘STOP’’ signal
upstream of the AML1 c-DNA curbs the expression of TEL-AML1
prior to Cre-mediated excision of ‘‘STOP.’’ As intended, mice
heterozygous for the ‘‘stopped’’ TEL-AML1 allele were normal
(data not shown), and homozygosity for the targeted allele
resulted in embryonic lethality due to loss of TEL function (data
not shown) (Hock et al., 2004b; Wang et al., 1997). Early embry-
onic excision of ‘‘STOP’’ was achieved by breeding with mice
harboring a Gata1-Cre promoter driven transgene (Figure S2).
While TEL-AML1 expression resulted in embryonic lethality in
30% of cases (Figures S2A, S2B, and S2E), 70% of mice
harboring TEL-AML1 alleles with the STOP-signal completely
excised were born alive. These mice were indistinguishable
from littermates, but failed to thrive and died in the postnatal
period with severe submucosal lymphedema of the small intes-
tine (Figures 1D–1F). Histologic analysis of the bone marrow of
pups expressing TEL-AML1 revealed no evidence of leukemia
(Figure 1G). Immunophenotypic analysis and enumeration of
early B cells failed to reveal differences between TEL-AML1-ex-
pressing pups and littermate controls (Figure 1H and 1I). Like-
wise, no significant difference in numbers or morphology of
IL-7-dependent colonies was observed (Figures 1J and 1K).
Thus, TEL-AML1 expression under control of the endogenous
TEL regulatory elements is permissive for normal B cell develop-
ment in the postnatal period and fails to elicit leukemia.
TEL-AML1 Expression in the Embryo Results in Subtle
Enhancement of B Cell Progenitor Self-Renewal and
Colony Number without Perturbing B Cell Maturation
TEL-AML1 expression caused early lethality (before embryonic
day (E) 10.5) in a fraction of embryos (30%) (Figure S2B and
data not shown). However, embryos that were viable at E10.5
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Figure 1. Recreation of the TEL-AML1 Fusion Oncogene in Mice
(A) In most cases of t(12;21) translocation, AML1 is fused to the intron between exon V (black) and exon VI (red) of the TEL locus (top, arrow). In the targeted allele
(middle), AML1 was engineered to replace exons VI and VII of TEL, and a loxP-flanked ‘‘STOP’’ signal prevents its expression. The ‘‘STOP’’ signal can be excised
by Cre to allow for expression of the fusion protein from the endogenous TEL promoter (bottom); for details see Figure S1.
(B) RT-PCR from pro-B cells shows that the TEL-AML1 transcript became abundant after excision by Cre recombinase. Sequence analysis confirmed correct
splicing; predicted amino acid residues for the entire breakpoint region shown are identical to those in the human leukemia.
(C) Immunoprecipitation followed by western blot analysis shows characteristic TEL-AML1 protein double band in pro-B cells after expression of Cre.
(D–F) Early embryonic expression of Cre results in ubiquitous, complete excision of the ‘‘STOP’’ signal (see Figure S2 for detailed of excision analysis) and leads to
almost complete postnatal lethality within the first 2 weeks in the majority of mice (D). Mutant pups die with dilated small bowel loops (E, arrow), severe submu-
cosal lymphedema, and inflammation of the small intestine (F, arrow; data not shown).
(G) During the first week of life, histology (hematoxylin and eosin stain after sectioning) of the bone marrow revealed no evidence of leukemia.
(H–K) Analysis of hematopoiesis in newborn mice after early, complete embryonic excision of the ‘‘STOP’’ signal (see Figure S2 for excision analysis). (H and I)
Flow cytometric analysis of B cell maturation revealed no abnormalities in the mutants: (H) representative analysis (day 5): upper panels, IgM+ B cells; middle
panels, pro-B cells (IgM, B220+, and CD43+) and pre-B cells (IgM, B220+, and CD43); lower panels, pro-B cell stages A (lower left), B (lower right), and C
(upper right). (I) Frequencies of B cell populations (cell numbers per 1000 bone marrow cells) from mice aged 3–5 days (controls n = 4, black bars; mutants
n = 4, red bars; p values > 0.05), error bars are standard deviations (SD). (J and K) IL-7-dependent colonies on day 3 after birth revealed no differences in frequency
(J) (colony number per 5 3 104 bone marrow cells seeded; n = 9 control; n = 12 mutants; error bars indicate SD; p value > 0.05) or morphology and size (K).were later indistinguishable from littermates regardless of the
presence and excision status of TEL-AML1 (Figure S2E; Figures
2A and 2B; data not shown), suggesting that TEL-AML1 did not
impede mid- and late embryonic development. Notably, we did
not observe embryos with abnormal yolk sac vasculature, a
finding characteristic of TEL loss (Wang et al., 1997). Thus,
despite evidence suggesting that TEL-AML1 protein might
sequester the product of the remaining normal TEL allele (Gunji
et al., 2004), expression of TEL-AML1 does not phenocopy
TEL loss (Figure 2A). Moreover, numbers of fetal liver cells
were normal (Figures 2B and 2C) suggesting that TEL-AML1 fails
to function as a dominant-negative inhibitor of CBF at the fetal
liver stage, unlike the fusion oncogenes AML1-ETO (Yergeau
et al., 1997) and CBFb-SMMHC (Castilla et al., 1996), or
in vitro-expressed TEL-AML1 (Hiebert et al., 1996).
Early B cell maturation in the fetal liver of TEL-AML1-expressing
embryos was ostensibly normal (Figure 2D) even though the
number of IL-7 colony progenitors was increased at E14.5
(Figure 2E). We observed no difference in serial replating potential
of fetal liver B cells in the presence of IL-7 alone (Figure 2F), but in
the presence of a combination of IL-7, stem cell factor (SCF), and
Flt3 ligand (Flt3L), serial replating potential was increased in TEL-
AML1-expressing early B cells. However, colonies could not bereplated indefinitely and never become factor independent
(Figure 2G and data not shown). These data demonstrate that
TEL-AML1 expression leads to subtle enhancement of self-
renewal in colony-forming B cell progenitors but does not block
B cell development in the embryo. Nevertheless, TEL-AML1 alone
was unable to transform fetal liver B cells, as its effects on early B
cell self-renewal were transient, the B cell compartment in
newborn mice was entirely normal, and serial re-plating potential
was not enhanced in newborns (Figure 1 and data not shown).
TEL-AML1 Expression by Fetal Liver Cells in the Adult
Bone Marrow Microenvironment Blocks Emergence
of Early B cells from HSCs without Affecting
B Cell Precursor Maturation
To assess the long-term fate of B cells derived from the fetal
liver in the bone marrow, we followed B cell reconstitution of irra-
diated B cell-deficient (RAG2/) mice after transplantation
of fetal liver (E14.5) cells in the absence or presence of TEL-
AML1 expression (Figures 3A–3E). Surprisingly, recipients of
TEL-AML1+ fetal liver cells exhibited significantly (p < 0.01)
reduced lymphocyte counts in the peripheral blood 2 months
after transplantation (Gata1-Cre/TEL-AML1: 3970 ± 439/ml,
n = 3; Gata1-Cre/wild-type 14820 ± 1254/ml, n = 5). Likewise,Cell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc. 45
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ment
(A) TEL-AML1 does not interfere with yolk sac
angiogenesis on embryonic day 10.5 (E10.5).
(B and C) TEL-AML1 does not interfere with effi-
cient fetal liver hematopoiesis; fetal livers are indis-
tinguishable in mutants and controls on E12.5 (B)
and E14.5 (data not shown). (C) Total fetal liver
cell numbers are not altered by TEL-AML1 (cells/
fetal liver/106 are shown; E12.5: control n = 22;
TA n = 9; E14.5: control n = 9; TA n = 9; E18.5:
control n = 6; TA n = 9). Averages and SDs are
shown; p values > 0.05.
(D) No difference in pro-B cell maturation marker in
E14.5 fetal livers.
(E) Increase in IL-7 colony numbers, but not colony
size, in the presence of TEL-AML1 at E14.5 (colony
numbers/105 fetal liver cells seeded; control, n = 6,
black bars; TA, n = 6, red bars; p value above
graph).
(F and G) Serial replating of E14.5 fetal liver cells in
IL7 alone (F; control n = 6; TA n = 6) or a combina-
tion of IL-7, SCF, and Flt3L (G, control n = 3, TA
n = 3). Colonies/5 3 105 fetal liver cells (E14.5)
seeded at the time of weekly replatings are shown.
No difference in replating potential with IL-7 alone;
prolonged, but finite, replating in IL-7, SCF, and
Flt3L. Note: only embryos that exhibited complete
excision of the ‘‘STOP’’ signal were included in the
analysis (see Figure S2 for excision data).TEL-AML1+ fetal liver cells failed to efficiently reconstitute proB-
cells, preB-cells, or IgM+ B cells in the bone marrow (Figures 3B
and 3C) but did give rise to myeloid cells as efficiently as control
fetal liver cells (Figure 3D). This finding suggests that hematopoi-
esis was sustained by TEL-AML1+ HSCs, but these specifically
failed to give rise to lymphoid cells. Thus, in marked contrast
to our findings in embryos and young mice, TEL-AML1 expres-
sion in fetal liver cells transplanted to the adult bone marrowA
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Figure 3. TEL-AML1 in B Cell Development
(A–E) Fetal liver cell transplantation reveals early B
cell differentiation block in the presence of TEL-
AML1 expression. (A) Scheme of experiment. (B)
B cells in the bone marrow 3 months after trans-
plantation of control or Tel-Aml+ fetal liver cells
(‘‘Stop’’-allele in donor cells completely excised
by Gata1-Cre, data not shown). IgM+ B cells
(upper panels, right frames), pre-B cells
(B220+CD43), and Pro-B cells (B220+CD43+)
(lower panels) are abundant in recipients of
control cells, but not recipients of Tel-Aml+ cells.
(C) Bar graphs show frequencies of B cell popula-
tions (cell numbers per 1000 bone marrow cells;
control n = 3; TEL-AML1 n = 5; averages and SD
are shown; p values above graphs). Note that B
cell deficiency includes the earliest stages of B
cell differentiation (Pro-B cells). (D) CD45-isotype
analysis confirms donor origin Gr1+ myeloid cell
in transplant recipients. (E) PCR analysis of DNA
from recipient bone marrow, confirming complete
excision of the ‘‘Stop’’ allele.
(F–H) B cell-specific induction of TEL-AML1 by
CD2-Cre. (F) Analysis of CD2-Cre-mediated exci-
sion of the ‘‘Stop’’ signal in DNA of selected hema-
topoietic populations by competitive PCR. Note
the absence of excision in hematopoietic stem cells (Lineage, cKit+, Sca1+, HSC-LKS+), granulocytes (Gr-1+), partial excision in common lymphoid progenitors
(CLP), and almost complete excision in early B cells and the thymus. (G and H) No difference in bone marrow B cell populations in 5-month-old mice; (G) IgM+ cells
(upper panels, right frames) and Pre-B and Pro-B cells (lower panels); (H) bar graphs show frequencies of B cell populations (cell numbers per 1000 bone marrow
cells; control n = 3; TEL-AML1 n = 3; averages and SD are shown; p values > 0.05). (I) Scheme of B cell block. Note that the B cell block observed experimentally
(solid line) occurs earlier than the differentiation arrest found in clinical leukemia samples (dotted line).46 Cell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc.
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Figure 4. Impact of TEL-AML1 Expression on HSCs and Lineage-Committed Progenitors in the Adult Bone Marrow
(A) Scheme of experiment.
(B) Frequencies (%) of bone marrow populations 2 to 3 months after pIpC-mediated Mx-Cre induction in control and TEL-AML1 knockin mice. From the left:
myeloid progenitors (LKS, lineage (L), c-Kit (K)+, Sca1 (S)); Control (Co) n = 6 and TEL-AML1 (TA) n = 6. Enriched HSCs (LKS+); Co n = 6 and TA n = 6. Highly
purified HSCs (LKS+, CD48 (48), CD150 (150)+); Co n = 6 and TA n = 6. Megakaryocyte/erythrocyte progenitors (MEPs), common myeloid progenitors (CMP),
and granulocyte/monocyte progenitors (GMP); Co n = 9 and TA n = 9. Common lymphoid progenitors (CLP); Co n = 4 and TA n = 4. Lymphoid-primed multipo-
tential progenitors (LMPP); Co n = 4 and TA n = 4. Averages and SD are shown; p values above bars.
(C-G) Representative plots of the HSC and progenitor populations, black numbers indicate proportion of gated cells (%) within the graph, gray numbers in
brackets indicate frequency of gated cells in relation to total cells in the bone marrow (%). Note: In the presence of TEL-AML1, HSCs and myeloid progenitors
are strikingly increased; CLPs and LMPPs are sharply decreased.
(H-J) Limiting dilution competitive-repopulation transplant. (H) Scheme of experiment; transplantation was performed6 weeks after pIpC injection. (I) Tabulated
results of FACS-analysis of bone marrow and blood 5 months after transplantation of the indicated number of control or TEL-AML1+ bone marrow cells together
with 180000 support (CD45.1+) cells to ensure survival. Note: At low numbers of transplanted bone marrow cells, recipients of TEL-AML1+ bone marrow cells have
detectable contribution to blood granulocytes more frequently than recipients of control cells. (J) Graphic representation of results; frequency of long-term
repopulating stem cells was determined with L-calc software (Stem Cell Technologies). Note: calculation of stem cell frequencies based on contribution to
granulocytes or LKS+ yielded similar results, i.e., stem cell frequency was elevated 10-fold in the presence of TEL-AML1.microenvironment is associated with a block in B cell develop-
ment. To further define the TEL-AML1-induced developmental
block, we bred mice expressing TEL-AML1 specifically in all
lymphoid cells as a consequence of CD2-promoter driven
Cre-expression. Despite efficient activation of TEL-AML1 by
Cre-mediated excision at the common lymphoid progenitor
(CLP) stage and thereafter (Figure 3F), TEL-AML1+ mice did not
display any differences in B cell development compared to control
mice (Figures 3G and 3H). These findings indicate that TEL-AML1
expression impairs emergence of early B cell progenitors from
HSCswithout affectingmaturationofB cell lineage cells (Figure3I).
TEL-AML1PerturbsHematopoietic StemandProgenitor
Cell Homeostasis in the Adult Bone Marrow
To comprehensively study the long-term impact of TEL-AML1 on
bone marrow hematopoiesis, we utilized Mx-Cre, which is
transiently expressed after administration of the IFN inducer
pIpC (Figure 4A). In the presence of Mx-Cre and the conditional
TEL-AML1 allele, pIpC injection mediated efficient stable exci-
sion of the STOP-signal in the bone marrow and resulted in
a persistent blood phenotype (Figures S3A and S3B). We
observed no selection for spontaneously excised cells in theabsence of pIpC injection (Figure S3B), suggesting that TEL-
AML1+ cells do not possess a significant competitive advantage
over wild-type cells. Despite TEL-AML1 expression, hematopoi-
esis remained remarkably stable for the lifetime of the animals.
These displayed only mild-to-moderate reductions in platelet,
lymphocyte, and neutrophil counts but did not develop progres-
sive blood abnormalities (Figure S3A and data not shown). In
contrast, TEL-AML1 expression resulted in striking alterations
in the frequency of HSCs and progenitors. The total number of
bone marrow cells (compared to pIpC-injected control mice)
was not changed in the face of TEL-AML1 expression
(Figure S3). However, CLPs and lymphoid-primed multipotential
progenitors (LMPPs), among the earliest cells committed to the
lymphoid lineage, were markedly reduced after TEL-AML1 induc-
tion (Figures 4B, 4F, and 4G). Accordingly, B cells were gradually
lost, as predicted by the fetal liver cell transplantation results
(Figures S3D and S3E). In contrast, TEL-AML1 expression led
to a marked increase of all myeloid progenitors and an 10-
fold increase in long-term repopulating HSCs (LKS+48150+)
(Figures 4B–4E; Figure S4). Importantly, all features of the TEL-
AML1-associated hematopoietic phenotype (including the
increase in myeloid progenitors, increase in HSCs, and loss ofCell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc. 47
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Leukemia Initiation by TEL-AML1B cells) were hematopoietic cell autonomous, as they were repro-
duced after transplantation of purified TEL-AML1+ HSCs
(LKS+48150+; 50 cells) into irradiated recipients (data not
shown). Recipients of TEL-AML1+ HSCs never reconstituted T-
or B cell compartments, consistent with a very early block in
lymphoid development before the LMPP or CLP stage (Figures
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Figure 5. Mechanism of HSC Expansion by TEL-AML1
Analysis 3 months after Mx-Cre activation.
(A) Cell-cycle stage distribution of HSCs (Lineage, cKit+, Sca1+, CD48,
CD150+) assessed by visualizing DNA content with Hoechst 33342 dye.
Shown are representative histograms; gates distinguish cells in G0/G1 from
cells in S/G2/M phases of the cell cycle. Numbers indicate the fraction of
cycling HSCs (%); shown are averages and standard deviations (SD), p =
0.01. Bar graphs indicate numbers of cycling HSCs per 106 total bone marrow
cells; averages and SD, control n = 6 (black) and TEL-AML1 n = 6 (red), p values
above graphs. Note that in the presence of TEL-AML1, a lower percentage of
HSCs cycled, but the total number of cycling HSCs in the bone marrow was
elevated. This results from the striking increase in HSCs in the bone marrow
(see Figures 4C and 4D).
(B) Analysis of quiescence of HSCs. Shown is one representative of three inde-
pendent experiments; plots show HSCs stained with Hoechst 33342 for DNA
and PyroninY for RNA content. Quiescent cells (G0, red frame) contain less
RNA than cells in S/G2/M and are in the left lower quadrant. Bar graphs
show the number of quiescent HSCs per 106 bone marrow cells; averages
and SD, control n = 3 (black) and TEL-AML1 n = 3 (red). Note that quiescent
HSCs in the bone marrow are17-fold elevated in the presence of TEL-AML1.
(C) Apoptosis of HSCs ex vivo in the absence of cytokines and serum. One of
three independent experiments is shown. Both TEL-AML1+ and control HSCs
(LSK+ and LSK+48150+) became apoptotic after removal from the bone
marrow microenvironment.48 Cell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc.4F and 4G; data not shown). To verify the increase in HSCs
independent of immunophenotypic marker profile and quantify
functional long-term repopulating activity, we performed limiting
dilution competitive repopulation assays of total bone marrow
(Figures 4H–4J). The early lymphoid block in the presence of
TEL-AML1 led to severely reduced donor-derived lymphocyte
numbers in recipient bone marrow and blood, which did not
adequately reflect stem cell activity (data not shown). However,
using donor contribution to blood granulocytes or bone marrow
HSCs (LKS+) as a measure of reconstitution, we calculated that
the number of functional long-term repopulating HSCs was
increased by 10-fold in the presence of TEL-AML1 (p <
0.0001; two-tailed t test). Finally, the TEL-AML1-associated
hematopoietic phenotype (including increase in HSC and
progenitor number and loss of B cells) was reproduced with
Vav-Cre, which excises in HSCs early in embryonic development
without need for an inducer (Figure S5 and data not shown). Thus,
TEL-AML1 expression perturbs the lymphoid differentiation
potential of HSCs in the adult bone marrow while dramatically
increasing their numbers.
TEL-AML1 Maintains HSCs at Higher Numbers
with Increased Quiescence
To explore the mechanisms of expansion of TEL-AML1+ HSCs,
we studied their cell-cycle profile and susceptibility to
apoptosis. The proportion of bone marrow TEL-AML1+ HSCs
(LKS+48150+) in active phases of the cell cycle was unexpect-
edly decreased compared to controls (Figure 5A, histograms).
However, since the overall number of HSCs in the bone marrow
was much higher in the presence of TEL-AML1 (Figures 4B and
4D), the total number of cycling HSCs among total bone marrow
cells was actually increased (Figure 5A, bar graph). Thus, the
TEL-AML1+ stem cell pool turns over slowly, yet because of its
increased size, produces higher numbers of cycling progeny.
In agreement with this, the vast majority of TEL-AML1+ HSCs
were in the G0 phase of the cell cycle (Figure 5B). In fact, the
proportion of quiescent (G0) HSCs among bone marrow cells
was 17-fold increased compared to controls (Figure 5B, bar
graph), suggesting that TEL-AML1 expression increased self-
renewal without compromising quiescence of the stem cell
pool. We also investigated whether failure to undergo apoptosis
contributed to the increased HSC number in the presence of
TEL-AML1. Immediately after isolation from the bone marrow,
the number of apoptotic HSCs was minimal regardless of the
presence or absence of TEL-AML1 (data not shown). After
24 hr in vitro without serum or cytokines, HSCs (LKS+ or
LKS+48150+) started to undergo apoptosis; indeed, apoptosis
was even more frequent in the presence of TEL-AML1
(Figure 5C). The latter finding raises the possibility that
TEL-AML1+ HSCs may be more sensitive to apoptotic stimuli
than normal HSCs and may be targeted preferentially in thera-
peutic interventions in the future. However, it is unlikely that
TEL-AML1+ HSCs harbor defects in proapoptotic pathways
sufficient to account for the greatly enlarged pool size.
TEL-AML1 Does Not Function as a Dominant Negative
of CBF in HSCs
Some features of the TEL-AML1-associated hematopoietic
phenotype, including reduction in platelet counts, increased
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Leukemia Initiation by TEL-AML1Figure 6. HSC Phenotype after Adult Disruption of AML1
Hematopoietic stem cells and progenitors 3 months after disruption of
AML1 in the bone marrow using Mx-Cre. Bar graphs show frequencies
of myeloid progenitors, enriched HSCs, and highly purified HSCs.
Averages and SD are shown. Control n = 3; AML1/ n = 3; p values
above graphs. Representative FACS plots on the right; black numbers
indicate proportion of gated cells (%) within the graph, and gray
numbers in brackets indicate frequency of gated cells in relation to
total cells in the bone marrow (%). Note that the number of highly puri-
fied HSCs was significantly reduced after disruption of AML1.myeloid progenitors, and loss of B cells, are also seen after
induced disruption of AML1 in adult mice (Growney et al.,
2005; Ichikawa et al., 2004). Superficially, these findings appear
consistent with the notion that TEL-AML1 acts as a dominant-
negative inhibitor of AML1 (Hiebert et al., 1996). Therefore, we
disrupted AML1 in adult mice using a conditional allele (Growney
et al., 2005) and directly compared the resulting phenotype to
our findings with TEL-AML1 (Figure 6). As expected, disruption
of AML1 caused loss of bone marrow B cells (data not shown),
an increase in myeloid progenitors, and an increase in the
LKS+ population, which is enriched in HSCs (Figure 6). Surpris-
ingly, but in agreement with the previous observation that
AML1/ bone marrow performed poorly in a competitive repo-
pulation assay (Growney et al., 2005), the number of long-term
repopulating HSCs (LKS+48150+) was significantly reduced
after disruption of AML1 (Figure 6). Thus, loss of AML1 and
expression of TEL-AML1 exert opposite effects on long-term
repopulating HSCs. These observations undermine the notion
that TEL-AML1 inhibits AML1 function in all contexts. Of note,
TEL-AML1 expression failed to rescue the loss of HSCs caused
by loss of AML1 and, therefore, does not appear to act simply by
augmenting normal functions of AML1 (Figure S6). Together,
these findings suggest that the TEL-AML1 fusion protein harbors
novel functions that are not easily explained by mere modulation
of the fusion partner AML1.
TEL-AML1 Expression in HSCs, but Not Early Lymphoid
Progenitors, Predisposes to Hematologic Malignancies
To determine if TEL-AML1 expression predisposes to leukemia
as implicit in its assignment as the initiating hit in childhood B
cell ALL, we monitored cohorts of mice expressing TEL-AML1
in HSCs (Mx-Cre) or specifically in lymphoid cells (CD2-Cre)
(Figure 7). In the absence of mutagen, TEL-AML1+ mice were
not prone to malignancies and remained without evidence of
disease (Figures 7A and 7C; data not shown). Since the TEL-
AML1 knockin allele leaves both endogenous copies of AML1
intact (whereas the clinical t(12;21) translocation additionally
disrupts one allele of AML1), we also generated cohorts of
mice that harbored one disrupted copy of AML1 in addition to
TEL-AML1 in HSCs. However, heterozygosity for AML1 did not
alter the hematopoietic phenotype of TEL-AML1+ mice
(Figure S7), and such mice also remained without evidence of
disease (n = 6; observed for >1 year; data not shown).
After challenge with a single dose of ENU (100 mg/kg), <30%
of control mice developed hematologic malignancies (mostly
T cell lymphomas and leukemias). When TEL-AML1 was ex-
pressed in early lymphoid cells, the latency and frequency oftumors after ENU challenge was unchanged (Figure 7B).
However, when TEL-AML1 was expressed in HSCs, the tumor
latency after ENU challenge was drastically shortened and
a higher proportion of mice developed malignancies (Figures
7D and 7E). Malignancies included aggressive T cell leukemias
with blast counts of up to 100,000 per ml of the peripheral blood
(data not shown) and subtotal replacement of normal bone
marrow hematopoiesis by CD4+CD8+ lymphoblasts (Figure 7F,
left panel), as well as early c-Kit-expressing leukemias that did
not express lineage markers (Figure 7F, right panel). Notably,
the difference in incidence of tumors in CD2-Cre- and Mx-Cre-
induced TEL-AML1+-mice was not associated with differences
in T cell development or excision efficiencies in the thymus
(Figure S8). B-lymphoblastic leukemias or myeloid leukemia
were not observed. Thus, recreation of TEL-AML1 expression
in mice predisposes to leukemic transformation, specifically
when activated in HSCs, yet the phenotypes of the induced
leukemias are not characteristic of typical B-ALL in humans.
DISCUSSION
We have engineered and analyzed conditional knockin mice for
TEL-AML1, the product of the chromosomal translocation that
initiates the most common form of childhood B-ALL. Our studies
reveal that TEL-AML1 has the potential to induce self-limited
expansion HSCs and render them quiescent but prone to trans-
formation, providing a novel mechanism for the initiation of acute
leukemia. Furthermore, we demonstrate that TEL-AML1 alters
the B cell differentiation potential of HSCs in a developmental-
stage-specific manner that may account for the childhood age
restriction of TEL-AML1 leukemia.
TEL-AML1 Corrupts Hematopoietic Stem Cells
As previous studies using heterologous promoters (Andreasson
et al., 2001; Fischer et al., 2005; Morrow et al., 2004; Tsuzuki
et al., 2004), we failed to detect direct transforming capacity of
TEL-AML1 (Figures 7A and 7C). However, in agreement with
findings in a p16Ink4a/p19Arf-deficient background (Bernardin
et al., 2002), we show that TEL-AML1 serves as a cooperating
oncogene after ENU mutagenesis. Moreover, we unexpectedly
discovered that TEL-AML1’s oncogenic activity requires expres-
sion in HSCs. While expression of TEL-AML1 in HSCs promoted
the development of lymphoid malignancies after ENU challenge
(Figure 7D), induced lineage-specific expression of TEL-AML1 in
very early lymphoid progenitors (starting at the CLP stage;
Figure 3F) failed to increase the propensity to develop tumors
after ENU (Figure 7B).Cell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc. 49
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expressed in HSCs for promoting malignancy is that lymphoid
progenitors lack self-renewal and are not sufficiently long-lived
to acquire the accessory mutations required for full transforma-
tion. Additionally, other aspects of the epigenetic state of stem
cells, such as altered repair mechanisms (Rossi et al., 2007) or
context-specific deregulation of oncogenes, may contribute to
the context-sensitive nature of TEL-AML1’s activity. In addition
to rendering HSCs prone to transformation, TEL-AML1 mark-
edly enhances their numbers in the adult bone marrow
(Figure 4). The combination of increased HSC numbers with
increased myeloid and decreased lymphoid potential is also
found in aging wild-type mice (Morrison et al., 1996), but in
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Figure 7. TEL-AML1 Predisposes to Hematologic Malignancies
after Cre-Mediated Activation in HSCs, but Not Early Lymphoid
Progenitors
(A and B) Expression of TEL-AML1 mediated by CD2-Cre does not result in
accelerated lethality compared to control mice (A), even after challenge with
ENU (B). (C and D) Expression of TEL-AML1 in HSCs mediated by Mx-Cre
does not result in premature death compared to controls in the absence of
mutagen (C) but causes accelerated malignancy after challenge with ENU
(D and E). Malignancies after ENU challenge were predominantly T cell malig-
nancies in both control and TEL-AML1+ mice (F, left panel; note that 88.4% of
total nucleated bone marrow cells were CD4+CD8+ T cells). In TEL-AML1+
mice, early progenitor leukemias were also seen (F, right panel; note that
31.7% of total nucleated bone marrow cells were lineage marker negative,
c-Kit positive [normal: 2%, data not shown]). Early B cell leukemias were
not observed.50 Cell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc.direct comparison, the age-associated changes in wild-type
bone marrow were subtle compared to those found in the pres-
ence of TEL-AML1 at any age (4 weeks–1.5 years, data not
shown). Moreover, aging HSCs turn over more frequently (Mor-
rison et al., 1996), while TEL-AML1+ HSCs were more quiescent
(Figure 5). The increased number of HSCs in the presence of
TEL-AML1 was the result of an altered steady state, and
HSCs did not progressively accumulate over time (data not
shown). Furthermore, wild-type and TEL-AML1+ HSCs coex-
isted in bone marrow of transplant recipients for at least
8 months without out-competing each other (data not shown),
and like wild-type HSCs, TEL-AML1+ HSCs eventually ex-
hausted in serial transplantation (Figure S9). Thus, TEL-AML1+
HSCs remain responsive to normal regulatory cues, which
eventually curb self-renewal, albeit at a greater pool size. In
agreement with these observations, TEL-AML1+ HSCs were
even more quiescent than wild-type HSCs (Figure 5), did not
show signs of exhaustion in sustaining blood formation over
the natural lifespan of mice (Figure 7; Figure S3A), and did not
exhibit markedly deregulated expression of major known regu-
lators of HSCs (Figure S10). We propose that the biology of
TEL-AML1-expressing HSCs is unique and compatible with its
role of the initiating hit in childhood B-ALL. TEL-AML1 expres-
sion expands and sustains altered HSCs that are available for
subsequent genetic insults. Yet, in contrast to MDS, CML, or
BCR-ABL+ ALL (Castor et al., 2005), where malignant HSCs
out-compete normal HSCs and dominate hematopoiesis,
premalignant TEL-AML1+ HSCs coexist with normal HSCs.
Thus, TEL-AML1 has the potential to create a reservoir of
leukemia-prone ‘‘corrupted’’ HSCs that remains limited in size
due to restraint by normal control mechanisms for HSCs.
Intriguingly, preservation of normal regulatory controls may
permit such corrupted HSCs to persist in the bone marrow
and avoid exhaustion. Our data suggest that in the clinical
setting, premalignant HSCs may be difficult to detect because
(1) they have the potential to exist as a very small clone among
an overwhelming majority of normal HSCs and (2) their progeny
are unlikely to exhibit obvious abnormalities. Accordingly, prior
to the development of overt TEL-AML1+ leukemia, children do
not exhibit obvious blood abnormalities, although TEL-AML1
can readily be amplified by PCR in the majority of cases
(Greaves, 2003). The initiating HSC lesion proposed in our
model is distinct from putative leukemia propagating stem cells
at later stages of the clinical disease (Castor et al., 2005; Hong
et al., 2008), but it may eventually give rise to such stem cells. At
the time of overt disease and in later stages of the preleukemic
phase, t(12;21)-associated leukemia can be sustained by cells
that are already committed to the B-lymphoid lineage (Castor
et al., 2005; Ford et al., 1998; Hong et al., 2008). Yet, sequence
analysis of TEL-AML1 breakpoints suggests that the majority of
translocations occur before B-lineage commitment (Tsai et al.,
2008). Moreover, at least in some instances, a premalignant
clone not yet committed to the B cell lineage persists sufficiently
long to give rise to more than one leukemic clone with identical
TEL-AML1 rearrangements but independent immunoglobulin
rearrangements (Pine et al., 2003; Weston et al., 2001). Thus,
it is likely that the striking effects of TEL-AML1 expression on
HSCs uncovered here reflect a critical aspect of its clinical pre-
leukemic activity.
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in Adult Mice
We demonstrate that TEL-AML1 expression prevents efficient B
cell development specifically in the adult bone marrow (Figures
3A–3E, 4F, and 4G; Figures S3D and S3E), but not in embryos
or very young mice (Figures 1H–1K, 2D, and 2E). Loss of B cells
in adult mice included all early B cell progenitors and precursors
and was therefore the result of failure of HSCs to initiate efficient
B cell differentiation rather than a maturation defect within the B
cell lineage. Expression analysis of known regulators of B cells in
early HSCs/progenitors (LK+S+) did not reveal an obvious
molecular mechanism for this block but did confirm decreased
expression of some early lymphoid genes such as Flt3 and
IL7-receptor (Figure S11). The precise stage of the B cell block
observed in our mice was unexpected because some (Fischer
et al., 2005; Tsuzuki et al., 2004), but not all (Andreasson et al.,
2001; Morrow et al., 2004), previous studies utilizing heterolo-
gous promoters reported a pro- to pre-B cell differentiation block
upon expression of TEL-AML1. An effect of TEL-AML1 at the
pre-pro-B-cell stage would be intriguing, as it might suggest
that TEL-AML1 could contribute directly to establishing the
phenotype of the bulk of the leukemic cells. However, in our
experiments, where TEL-AML1 expression is driven by the
endogenous locus as occurs in the human leukemia, neither an
increase in pro-B-cells nor a differentiation block at the pro-B
to pre-B transition were apparent (Figures 1H and 3G; Figures
S3D and S3E). It is unlikely that the B cell block that we have
uncovered contributes directly to the maturation block associ-
ated with TEL-AML1+ leukemia, which occurs later in B cell
development (Panzer-Grumayer et al., 2005). In contrast, this
block may protect adults from leukemia by preventing the forma-
tion of critical early lymphoid target cells that are required for
promoting leukemia. In agreement with this, adults only rarely,
if ever, develop TEL-AML1+ leukemia even though TEL-AML1
can be amplified frequently from adult blood samples (Eguchi-
Ishimae et al., 2001; Olsen et al., 2006). It has recently been re-
vealed that at least some aspects of the molecular program
that regulate fetal hematopoiesis persist until the second month
of life in the mouse (Kim et al., 2007), which is also the time when
the TEL-AML1 mediated block in B cell development develops
(data not shown). We hypothesize that TEL-AML1 initiates
leukemia in HSCs, but unless they give rise to B-lineage-
committed leukemic cells or preleukemic cells before the switch
to adult hematopoiesis occurs, HSCs become innocuous by
losing their potential to give rise to B cells and leukemia.
Early Fetal Liver B Cells Are Uniquely Susceptible
to TEL-AML1
Our study suggests that early fetal liver B cell progenitors are
specifically susceptible to modulation of their self-renewal
capacity by TEL-AML1 (Figures 2F and 2G). This confirms and
extends findings of retroviral gene transfer of TEL-AML1 (Morrow
et al., 2004) into fetal liver cells. At E14.5, TEL-AML1+ embryos
harbored significantly more IL-7-dependent colony-forming
progenitors than littermates, and TEL-AML1+ colonies could be
serially replated more efficiently when additional early acting
cytokines (SCF, Flt3L, and IL-7) were added. It is critical to
note, however, that these effects were subtle and self-renewal
was merely prolonged, but not sustained. Moreover, theseeffects were transient in vivo such that in the postnatal period,
IL-7-dependent colony progenitors were not different in the
presence of TEL-AML1 (Figures 1J and 1K) and could not be re-
plated at higher efficiency (Figure S4E). Nevertheless, intrinsic
features specific to fetal liver B cells may contribute to the early
preleukemic pathogenesis associated with TEL-AML1, a notion
that is in agreement with recent findings suggesting that TEL-
AML1 increases the self-renewal potential of early B cells in
human cord blood (Hong et al., 2008).
Development of Childhood B-ALL Involves Multiple
Genetic Hits
Thus far, no experimental model of t(12;21)-associated leukemia
has recapitulated the full disease phenotype of B-ALL, irrespec-
tive of the mode and timing of expression or the source of target
cells (Andreasson et al., 2001; Bernardin et al., 2002; Fischer
et al., 2005; Hong et al., 2008; Morrow et al., 2004; Tsuzuki
et al., 2004). In one small study using retroviral gene transfer, a
single case of B cell leukemia with unclear maturation stage
was documented, but so were several cases of T cell leukemia
and myeloid leukemia (Bernardin et al., 2002). In a zebrafish
model, a 3% incidence of early lymphoid leukemia was reported,
but it was not conclusively shown whether these were of B- or
T cell origin (Sabaawy et al., 2006). We primarily observed malig-
nancies in the T-lymphoid lineage following mutagenesis. The
inability to generate B-ALL may reflect the requirement for
specific secondary molecular hits, which are not introduced effi-
ciently by nonspecific mutagenesis strategies. Of note, our
experimental system has incorporated three critical molecular
changes that directly result from the initial translocation: (1)
TEL-AML1 expression from the endogenous TEL promoter, (2)
loss of one copy of TEL (a result of the knockin), and (3) loss of
one copy of AML1 (using a conditional AML1 allele; Figure S7;
data not shown). However, recent genome-wide searches
have revealed multiple additional recurrent genetic abnormalities
in TEL-AML1-associated leukemia, including loss of the second
TEL allele, heterozygousity for Pax5, and heterozygousity of the
p16Ink4a/p19Arf (Mullighan et al., 2007). Experiments are
underway to test whether addition of one or more of these
molecular abnormalities will result in pro-B cell leukemia.
Concluding Remarks
The multistep process that ultimately leads to the onset of acute
leukemia remains poorly understood, particularly those events
that initiate the cascade. Our study reveals that HSCs are
susceptible to ‘‘corruption’’ by a weak oncogene, TEL-AML1,
which does not directly transform them but subverts them to
create a persistent premalignant lesion available for the accumu-
lation of further genetic hits. Surprisingly, these premalignant
HSCs retain many features of normal HSCs, including their
potential to sustain hematopoiesis, quiescence, and small pop-
ulation size. The restrained self-renewal of premalignant stem
cells provides an explanation for the difficult detection and
covert nature of the premalignant phase of acute leukemia.
Our findings illustrate that it may be advantageous for weak
oncogenes that lack direct transforming potential to preserve
the regulatory control mechanisms of normal stem cells to
persist in their niche and avoid exhaustion. Further investigation
into the biology of premalignant stem cells may educate us howCell Stem Cell 5, 43–53, July 2, 2009 ª2009 Elsevier Inc. 51
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progression to malignancy.
EXPERIMENTAL PROCEDURES
Mice
Conditional TEL-AML1 knockin mice were generated after targeting CJ7 ESCs
(129) (see Figure S1 and Supplemental Experimental Procedures for details)
and backcrossed to C57/bl6 mice for >8 generations. All other mouse strains
are detailed in the Supplemental Data.
pIpC Treatment
Mx-Cre-mediated excision was achieved by intraperitoneal injection of pIpC.
The exact dose and schedule was tested for each batch of pIpC to ensure
complete excision in the bone marrow: GE Healthcare pIpC (27-4732-01;
Lot FL0182), total of 4 injections every other day at 8.5 mg/kg mouse weight.
Flowcytometry
A modified FACS ARIA with five lasers (UV 300 nm, violet 405 nm, blue 488 nm,
green 532 nm, and red 633 nm) or a standard 3 laser FACSCalibur were used
for flowcytometry. Immunostains were performed as described (Foudi et al.,
2009; Hock et al., 2004a, 2004b). For sorting HSCs, lineage-negative bone
marrow cells were enriched using streptavidin-magnetic beads (M-280,
Invitrogen) and a biotinylated lineage antibody cocktail. Subsequently, cells
were stained with appropriate fluorchrome-conjugated HSC markers,
including PE-Cy5-conjugated lineage cocktail. Residual biotinylated anti-
bodies were detected with streptavidin-PE-Cy5 and HSCs isolated by two
rounds of FACS-sorting to achieve purity. For a list of all antibody combina-
tions used for analysis of HSCs, progenitors, cell-cycle assays, and apoptosis
assays, see the Supplemental Data.
Bone Marrow Transplantation
Bone marrow transplantations were performed by intravenous injection of
donor cells (CD45.2) with 2 3 105 competitor bone marrow (B6.SJL,
CD45.1) into recipients (B6.SJL, CD45.1) that had received 1200 cGy of radi-
ation as a split dose at least 3 hr apart as previously described (Hock et al.,
2004a, 2004b). In case of transplants into Rag2//CD45.1 mice, no compet-
itor cells were given, and the radiation dose was reduced to 900 cGy.
Mutagenesis and Leukemia Surveillance
Mice with appropriate TEL-AML1 gene status and controls were monitored for
the development of leukemia by analysis of peripheral blood (complete blood
count and blood smears; Hock et al. [2003]) every 4 to 12 weeks. Mice were
euthanized as soon as they developed malignancy or reached other endpoints
set to meet accepted animal care guidelines. At the time of euthanasia or spon-
taneous mortality, necropsy and flowcytometry of bone marrow, spleen, and
thymus were performed when possible. For mutagenesis, mice were injected
intraperitoneally with a single dose of ENU (Sigma 3385) at a dose of 100 mg/kg
mouse weight.
Statistical Analysis
Significance was determined by two-tailed Student’s t tests.
SUPPLEMENTAL DATA
The Supplemental Data include 12 figures and Supplemental Experimental
Procedures and can be found with this article online at http://www.cell.com/
cell-stem-cell/supplemental/S1934-5909(09)00208-2.
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